Bristol, UK – 30th January, 2008, Apitope Technology (Bristol) Ltd., the developer of peptide-based therapies for autoimmune diseases and allergy, announces today final results of a Phase I/IIa clinical trial of ATX-MS-1467 to treat Multiple Sclerosis (MS). (more..)
Bristol, UK, 5th November 2007, Apitope Technology (Bristol) Ltd., the developer of peptide-based therapies, announces the completion of dosing for all six Multiple Sclerosis (MS) patients in a Phase I/IIa trial of ATX-MS-1467. The therapeutic vaccine was found to be safe and well tolerated in Secondary Progressive Multiple Sclerosis (SPMS) patients. (more..)
Bristol, UK, 10th July 2007 Apitope Named as Runner-up in Top British Bio Award for Innovation in Drug Discovery & Development (more..)
Bristol, UK, 6 February 2007: Apitope Technology (Bristol) Ltd, the developer of peptide-based vaccine therapies for autoimmune and allergic conditions, announces that it has received regulatory approval to start a Phase I study of its therapeutic vaccine in MS patients. (more..)
Bristol, UK, 18 September 2006, Apitope Technology (Bristol) Ltd, the developer of peptide-based therapies, is pleased to announce the publication of preclinical results in the Journal of Neuroimmunology. The results further demonstrate the role of interleukin-10 (IL-10) in peptide therapies to treat Multiple Sclerosis (MS) and other autoimmune diseases. (more..)
Bristol, UK, 18th April 2006, . The UK-based therapeutic peptide experts, Apitope®, have secured development funding worth £0.91 million from the Wellcome Trust and announced the appointment of Dr Keith Martin as the new CEO. Dr Martin who has a successful 20-year track record in R&D, corporate and business development and biotech start-ups will work closely with immunology expert Professor David Wraith, the company’s founder and Research Director. (more..)
News
